60 Degrees Pharmaceuticals, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.60degreespharma.com

Moat Score

Market Cap $3.03M
PE -0
Debt $158.77K
Cash $3.45M
EV -$263.76K
FCF -

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$10.74M
EBIT	-$10.26M
ROE	-261%
ROA	-172%
Equity	$4.11M
Growth Stability	1
PE	-0.28
PB	0.74
P/S	4.63
Price/Cash	1.14
Debt/Equity	0.04
Net Margins	-1K%
Gross Margins	40%
Op. Margins	-2K%
Sales Growth YoY	40%
Sales Growth QoQ	-29%
Sales CAGR	103%
Equity CAGR	-12%
Earnings Growth YoY	-749%
Earnings Growth QoQ	-8%

Sales CAGR 5Y	103%
Equity CAGR 5Y	-12%
Earnings CAGR 3Y	132%
Sales CAGR 3Y	132%
Equity CAGR 3Y	-17%
Market Cap	$3.03M
Revenue	$654.66K
Assets	$5.98M
Total Debt	$158.77K
Cash	$3.45M
Shares Outstanding	1.28M
EV	-263.76K
Moat Score	0%
Working Capital	3.85M
Current Ratio	3.13
Gross Profit	$262.06K
Shares Growth 3y	30%
Equity Growth QoQ	2%
Equity Growth YoY	-43%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Company's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue.

SEC Filings

Direct access to 60 Degrees Pharmaceuticals, Inc. (SXTP) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30

Sector Comparison

How does 60 Degrees Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of 60 Degrees Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

60 Degrees Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for 60 Degrees Pharmaceuticals, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2022	12/2023	12/2024	TTM
Net Margins	-3K%	-2K%	-1K%	-1K%
ROA	-	-49%	-138%	-172%
ROE	-	-81%	-209%	-261%

Bad Net Margins (-1.23K%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-0.03	-
Debt over Equity	-0.31	0.3	0.04	0.04
Growth Stability	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.04)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	14%	140%	103%
Earnings YoY growth	-	-37%	115%	-
Equity YoY growth	-	-121%	-17%	-12%
FCF YoY growth	-	-	25%	-